Skip to main content
Erschienen in:

13.10.2022 | Original Research

National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use

verfasst von: Chelsea Richwine, PhD, Jordan Everson, PhD

Erschienen in: Journal of General Internal Medicine | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Despite widespread adoption of state prescription drug monitoring programs (PDMPs), it is unclear how often PDMPs are accessed through an electronic health record system (EHR-PDMP integration), or whether efforts to make PDMPs easier to access and use have improved their utility.

Objective

To produce national-level estimates on the use of PDMPs among office-based physicians and benefits associated with their use.

Design

We use nationally representative survey data to produce descriptive statistics on PDMP use and associated benefits among office-based physicians in the USA.

Participants

1398 office-based physicians who prescribe controlled substances.

Main Measures

We examined physician-reported ease and frequency of PDMP use, and how EHR-PDMP integration affects frequency and ease of use. Multivariate models were used to assess whether characteristics of PDMP use were related to physician-reported benefits such as reduced prescribing of controlled substances and perceived improvements in clinical decision-making.

Key Results

In 2019, two-thirds of office-based physicians in the USA reported frequent use of their state PDMP and over three-quarters reported they were easy to use. Both frequency and ease of use were positively correlated with PDMP integration status. Respondents who frequently checked their state’s PDMP were 8.7 percentage points (95% CI −.4 to 17.8) more likely to report perceived benefits and reported 2.2 (95% CI 1.54 to 2.83) more benefits. Respondents who indicated their PDMP was easy to use were 12.7 percentage points (95% CI .040 to .214) more likely to report perceived benefits and reported 0.94 (95% CI 0.26 to 1.61) more benefits.

Conclusions

Our findings suggest efforts to make PDMPs easier to access and use aided physicians in making informed clinical decisions that may not be captured by reduced prescribing alone. Efforts to further increase frequency and ease of use—including advancing a standards-based approach to PDMP and EHR data interoperability—may further increase the benefit of PDMPs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat National Center for Injury Prevention and Control (U.S.). Division of Unintentional Injury Prevention. Integrating & Expanding Prescription Drug Monitoring Program Data: Lessons from Nine States. (February 2017). Available from: https://stacks.cdc.gov/view/cdc/45241 National Center for Injury Prevention and Control (U.S.). Division of Unintentional Injury Prevention. Integrating & Expanding Prescription Drug Monitoring Program Data: Lessons from Nine States. (February 2017). Available from: https://​stacks.​cdc.​gov/​view/​cdc/​45241
6.
Zurück zum Zitat Davis C, Sargent W, Vick J, Kuoh H, Cote P-O. Leveraging Prescription Drug Monitoring Program (PDMP) Data in Overdose Prevention and Response. Available from: https://stacks.cdc.gov/view/cdc/108523 Davis C, Sargent W, Vick J, Kuoh H, Cote P-O. Leveraging Prescription Drug Monitoring Program (PDMP) Data in Overdose Prevention and Response. Available from: https://​stacks.​cdc.​gov/​view/​cdc/​108523
7.
Zurück zum Zitat Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23(5):297-303. Nam YH, Shea DG, Shi Y, Moran JR. State prescription drug monitoring programs and fatal drug overdoses. Am J Manag Care. 2017;23(5):297-303.
8.
Zurück zum Zitat Bao Y, Wen K, Johnson P, Jeng PJ, Meisel ZF, Schackman BR. Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions. Health Affairs. 2018;37(10):1596-604. Bao Y, Wen K, Johnson P, Jeng PJ, Meisel ZF, Schackman BR. Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions. Health Affairs. 2018;37(10):1596-604.
9.
Zurück zum Zitat Grecu AM, Dave DM, Saffer H. Mandatory access prescription drug monitoring programs and prescription drug abuse. J Policy Anal Manage. 2019;38(1):181-209. Grecu AM, Dave DM, Saffer H. Mandatory access prescription drug monitoring programs and prescription drug abuse. J Policy Anal Manage. 2019;38(1):181-209.
10.
Zurück zum Zitat Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse Res Treat. 2009;3:SART. S2345. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Subst Abuse Res Treat. 2009;3:SART. S2345.
11.
Zurück zum Zitat Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747-54. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747-54.
12.
Zurück zum Zitat Rhodes E, Wilson M, Robinson A, Hayden JA, Asbridge M. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Serv Res. 2019;19(1):1-11. Rhodes E, Wilson M, Robinson A, Hayden JA, Asbridge M. The effectiveness of prescription drug monitoring programs at reducing opioid-related harms and consequences: a systematic review. BMC Health Serv Res. 2019;19(1):1-11.
13.
Zurück zum Zitat Heather DM, Modi SS, Feldman SS. Barriers and facilitators to PDMP IS Success in the US: a systematic review. Drug Alcohol Depend. 2020:108460. Heather DM, Modi SS, Feldman SS. Barriers and facilitators to PDMP IS Success in the US: a systematic review. Drug Alcohol Depend. 2020:108460.
15.
Zurück zum Zitat Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. Clinicians’ use of prescription drug monitoring programs in clinical practice and decision-making. Pain Med. 2017;18(6):1063-9. Leichtling GJ, Irvine JM, Hildebran C, Cohen DJ, Hallvik SE, Deyo RA. Clinicians’ use of prescription drug monitoring programs in clinical practice and decision-making. Pain Med. 2017;18(6):1063-9.
16.
Zurück zum Zitat Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):1-8. Finley EP, Garcia A, Rosen K, McGeary D, Pugh MJ, Potter JS. Evaluating the impact of prescription drug monitoring program implementation: a scoping review. BMC Health Serv Res. 2017;17(1):1-8.
17.
Zurück zum Zitat Smith RJ, Kilaru AS, Perrone J, Paciotti B, Barg FK, Gadsden SM, et al. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs? Pain Med. 2015;16(6):1122-31. Smith RJ, Kilaru AS, Perrone J, Paciotti B, Barg FK, Gadsden SM, et al. How, why, and for whom do emergency medicine providers use prescription drug monitoring programs? Pain Med. 2015;16(6):1122-31.
18.
Zurück zum Zitat Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff. 2015;34(3):484-92. Rutkow L, Turner L, Lucas E, Hwang C, Alexander GC. Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff. 2015;34(3):484-92.
19.
Zurück zum Zitat Poon SJ, Greenwood-Ericksen MB, Gish RE, Neri PM, Takhar SS, Weiner SG, et al. Usability of the Massachusetts prescription drug monitoring program in the emergency department: A mixed-methods study. Acad Emerg Med. 2016;23(4):406-14. Poon SJ, Greenwood-Ericksen MB, Gish RE, Neri PM, Takhar SS, Weiner SG, et al. Usability of the Massachusetts prescription drug monitoring program in the emergency department: A mixed-methods study. Acad Emerg Med. 2016;23(4):406-14.
20.
Zurück zum Zitat Perez NM, Jennings WG, Wang Y, Delcher C. Law enforcement officers’ perceptions of Florida’s prescription drug monitoring program. J Contemp Crim Justice. 2017;33(4):368-79. Perez NM, Jennings WG, Wang Y, Delcher C. Law enforcement officers’ perceptions of Florida’s prescription drug monitoring program. J Contemp Crim Justice. 2017;33(4):368-79.
21.
Zurück zum Zitat Goodin AJ, Brown JD, Delcher C, Freeman PR, Talbert J, Henry SG, et al. Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Res Social Adm Pharm. 2020;16(9):1306-8. Goodin AJ, Brown JD, Delcher C, Freeman PR, Talbert J, Henry SG, et al. Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Res Social Adm Pharm. 2020;16(9):1306-8.
25.
Zurück zum Zitat Robinson A, Wilson MN, Hayden JA, Rhodes E, Campbell S, MacDougall P, et al. Health care provider utilization of prescription monitoring programs: a systematic review and meta-analysis. Pain Med. 2021. Robinson A, Wilson MN, Hayden JA, Rhodes E, Campbell S, MacDougall P, et al. Health care provider utilization of prescription monitoring programs: a systematic review and meta-analysis. Pain Med. 2021.
26.
Zurück zum Zitat Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff. 2017;36(4):733-41. Wen H, Schackman BR, Aden B, Bao Y. States with prescription drug monitoring mandates saw a reduction in opioids prescribed to Medicaid enrollees. Health Aff. 2017;36(4):733-41.
27.
Zurück zum Zitat Lin H-C, Wang Z, Boyd C, Simoni-Wastila L, Buu A. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav. 2018;76:348-54. Lin H-C, Wang Z, Boyd C, Simoni-Wastila L, Buu A. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain. Addict Behav. 2018;76:348-54.
28.
Zurück zum Zitat Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C, Castillo-Carniglia A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Intern Med. 2018;168(11):783-90. Fink DS, Schleimer JP, Sarvet A, Grover KK, Delcher C, Castillo-Carniglia A, et al. Association between prescription drug monitoring programs and nonfatal and fatal drug overdoses: a systematic review. Ann Intern Med. 2018;168(11):783-90.
29.
Zurück zum Zitat Albright DL, McDaniel J, Laha-Walsh K, Morrison B, McIntosh S. Polysubstance abuse associated with more frequent opioid use among patients in rural primary care settings. J Opioid Manag. 2020;16(4):283-9. Albright DL, McDaniel J, Laha-Walsh K, Morrison B, McIntosh S. Polysubstance abuse associated with more frequent opioid use among patients in rural primary care settings. J Opioid Manag. 2020;16(4):283-9.
30.
Zurück zum Zitat Van Rijswijk S, van Beek M, Schoof G, Schene A, Steegers M, Schellekens A. Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: a systematic review. Gen Hosp Psychiatry. 2019;59:37-50. Van Rijswijk S, van Beek M, Schoof G, Schene A, Steegers M, Schellekens A. Iatrogenic opioid use disorder, chronic pain and psychiatric comorbidity: a systematic review. Gen Hosp Psychiatry. 2019;59:37-50.
31.
Zurück zum Zitat Matos A, Bankes DL, Bain KT, Ballinghoff T, Turgeon J. Opioids, polypharmacy, and drug interactions: a technological paradigm shift is needed to ameliorate the ongoing opioid epidemic. Pharmacy. 2020;8(3):154. Matos A, Bankes DL, Bain KT, Ballinghoff T, Turgeon J. Opioids, polypharmacy, and drug interactions: a technological paradigm shift is needed to ameliorate the ongoing opioid epidemic. Pharmacy. 2020;8(3):154.
32.
Zurück zum Zitat Stogner JM, Sanders A, Miller BL. Deception for drugs: self-reported “doctor shopping” among young adults. J Am Board Fam Med. 2014;27(5):583-93. Stogner JM, Sanders A, Miller BL. Deception for drugs: self-reported “doctor shopping” among young adults. J Am Board Fam Med. 2014;27(5):583-93.
33.
Zurück zum Zitat Han H, Kass PH, Wilsey BL, Li CS. Increasing trends in Schedule II opioid use and doctor shopping during 1999–2007 in California. Pharmacoepidemiol Drug Saf. 2014;23(1):26-35. Han H, Kass PH, Wilsey BL, Li CS. Increasing trends in Schedule II opioid use and doctor shopping during 1999–2007 in California. Pharmacoepidemiol Drug Saf. 2014;23(1):26-35.
38.
Zurück zum Zitat Strickler GK, Zhang K, Halpin JF, Bohnert AS, Baldwin GT, Kreiner PW. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019;199:1-9. Strickler GK, Zhang K, Halpin JF, Bohnert AS, Baldwin GT, Kreiner PW. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing. Drug Alcohol Depend. 2019;199:1-9.
Metadaten
Titel
National Estimates and Physician-Reported Impacts of Prescription Drug Monitoring Program Use
verfasst von
Chelsea Richwine, PhD
Jordan Everson, PhD
Publikationsdatum
13.10.2022
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 4/2023
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-022-07793-x

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Koronare Herzkrankheit: Das waren die Top-Studien in 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Inhalative Steroide bei COPD nicht kardioprotektiv

  • 10.01.2025
  • COPD
  • Nachrichten

Ob inhalative Kortikosteroide (ICS) COPD-Kranke außer vor akuten Exazerbationen auch vor kardiovaskulären Komplikationen schützen können, ist unklar. Eine bevölkerungsbasierte Studie aus England spricht nicht dafür.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.